Every material Form 8-K Abbott Laboratories filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
On December 12, 2025, Abbott Laboratories named Nita Ahuja, M.D. to its Board of Directors. The same day, the board amended the by-laws to set the board at thirteen persons, up from twelve, effective December 12, 2025. The filing does not describe Dr. Ahuja's background, committee roles, or compensation.
Nita Ahuja, M.D. was named to the Board of Directors on December 12, 2025.
Article III, Section 2 of the by-laws was amended so the board consists of thirteen persons, up from twelve.
The amended and restated by-laws are filed as Exhibit 99.1, effective December 12, 2025.
Abbott agreed on November 19, 2025 to acquire Exact Sciences in a cash deal valued at about $21 billion in equity and $23 billion in enterprise value, with closing expected in the second quarter of 2026. Abbott said the deal is dilutive to adjusted earnings per share through 2027 and expects it to be accretive in 2028 and beyond, so the acquisition has a near-term cost to Abbott's per-share earnings.
Exact Sciences shareholders will receive $105 per common share in cash, subject to a shareholder vote and regulatory approvals.
Abbott's adjusted EPS impact is dilutive: ($0.20) in 2026 and ($0.16) in 2027, with accretion expected in 2028.
Abbott has a $20 billion senior unsecured bridge loan commitment from Morgan Stanley Senior Funding, Inc.
Abbott expects at least $100 million in annual pre-tax synergies by 2028 and an initial 2026 adjusted gross debt-to-EBITDA ratio of about 2.7x.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Abbott Laboratories filing is on SEC EDGAR ↗. 8-K briefs of other companies →